X

Trial Profile

A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Corticosteroids; Remdesivir
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms RuxCoFlam

Most Recent Events

01 Sep 2023 Primary endpoint has been met (overall response rate in reversal of hyperinflammation) , acceding to Results published in the Leukemia
01 Sep 2023 Results published in the Leukemia
15 Jun 2023 Results assessing potential of ruxolitinib in addition to standard of care in the treatment of Covid19 patients with defined hyperinflammation and ongoing or imminent organ failure, presented at the 28th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com